PRASFIT-ACS Study: PRASugrel Compared to Clopidogrel For Japanese PatIenTs with ACS Undergoing PCI

Trial Profile

PRASFIT-ACS Study: PRASugrel Compared to Clopidogrel For Japanese PatIenTs with ACS Undergoing PCI

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2016

At a glance

  • Drugs Prasugrel (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PRASFIT-ACS
  • Sponsors Daiichi Sankyo Company; Ube Industries
  • Most Recent Events

    • 20 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI101339)
    • 22 Apr 2014 Primary endpoint 'Major-adverse-cardiac-event-rate' has been met.
    • 22 Apr 2014 Results published in the Circulation Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top